Search results
Results from the WOW.Com Content Network
Ketamine has been tested as a rapid-acting antidepressant [13] for treatment-resistant depression in bipolar disorder, and major depressive disorder. [14] Spravato, a nasal spray form of esketamine, was approved by the FDA in 2019 for use in treatment-resistant depression when combined with an oral antidepressant. [15] [16]
A 2021 article published in Nature reports increased risk of depression, anxiety, sleep problems, and substance use disorders among post-acute COVID-19 patients. [30] In 2020, a Lancet Psychiatry review reported occurrence of the following post-COVID-19 psychiatric symptoms: traumatic memories (30%), decreased memory (19%), fatigue (19% ...
COVID-19 increases fear and worries of vulnerability due to the unclear understanding of how COVID-19 impacts pregnancy. A 2020 study in China of 4,124 pregnant women found that after they learned that COVID-19 could be spread from human to human their scores on the Edinburgh Postnatal Depression Scale were much higher.
The risk factors [110] for treatment resistant depression are: the duration of the episode of depression, severity of the episode, if bipolar, lack of improvement in symptoms within the first couple of treatment weeks, anxious or avoidant and borderline comorbidity and old age. Treatment resistant depression is best handled with a combination ...
For treatment-resistant depression, adding on the atypical antipsychotic brexpiprazole for short-term or acute management may be considered. [209] Brexpiprazole may be effective for some people, however, the evidence as of 2023 supporting its use is weak and this medication has potential adverse effects including weight gain and akathisia. [209]
The COVID-19 pandemic has had many impacts on global health beyond those caused by the COVID-19 disease itself. It has led to a reduction in hospital visits for other reasons. There have been 38 per cent fewer hospital visits for heart attack symptoms in the United States and 40 per cent fewer in Spain. [1]
Treatment-resistant depression is when a person’s depression doesn’t respond to at least two different types of antidepressants. About 30% of people with major depressive disorder do not ...
Treatment-resistant depression This page was last edited on 20 December 2023, at 20:06 (UTC). Text is available under the Creative Commons Attribution ...